Hemorrhoids
Conditions
Brief summary
Evaluation of the effect and safety of NeoFitoroid® in reducing symptoms in patients with hemorrhoidal disease.
Detailed description
Evaluation of the effect and safety of NeoFitoroid® in relieving discomfort symptom after 10 days of treatment compared to baseline (pretreatment). The study duration per patient is 31 days (visit 1 + 10 days treatment + 20 days follow-up).
Interventions
DEVICENeofitoroid®
NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
Sponsors
GB Pharma Group
Aboca Spa Societa' Agricola
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients of both sexes ≥ 18 years . 2. Diagnosis of hemorrhoidal disease of grade I or II, non thrombosed, according to Goligher's classification performed by anoscopy/rectoscopy at screening. 3. Patient is not expected to require non-pharmacological (as Sclerotherapy, Rubber band ligation, Infrared Coagulation, Radiofrequency Ablation, Cryotherapy) or surgical treatment in the 31 days post enrollment . 4. Discomfort score related to the hemorrhoidal disease ≥ 30 measured through a 0-100 Visual Analog Scale VAS (from no symptoms to overwhelming symptoms) at screening. 5. Women of childbearing potential undergone a negative pregnancy test. 6. Informed consent documentation signed and dated confirming that the patient has been adequately informed of all aspects related to his/her participation in the clinical study and is willing to participate.
Exclusion criteria
1. Patients with gastrointestinal disease like inflammatory bowel disease, celiac disease, colo-rectal cancer, perianal/fistulizing disease). 2. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and/or that, in the judgment of the investigator, would make the subject inappropriate for entry into this study. 3. Patients with active cancer. 4. Tubercolosis , mycosis, Herpes Symplex, virologic disease with anal or perianal skin localization. 5. Presence of physical and/or mental disability that reduces the ability to take medicines as expected. 6. Concomitant abuse of drugs or alcohol. 7. No adequate reliability or presence of conditions that may result in non-compliance / adherence of the patient to the Protocol. 8. Subjects with known or suspected allergy to plants of Helichrysum family, aloe vera, Ruscus, Hypericum, Jojoba Oil, Shea Butter, Essential oils of: Melaleuca, Cypress and Peppermint. 9. Subjects with known or suspected allergy to ingredients such as: glicerilstearato, Caprylic / capric, sucrose distearate, sucrose stearate, cetearyl alcohol, vegetable glycerin, triidrossistearina, vegetable oils, hydrogenated vegetable oils, Candelilla wax, xanthan gum, citric acid, tocopherols, sodium silicate, benzyl alcohol, potassium sorbate, sodium dehydroacetate, Sunflower oil. 10. Subjects with the presence of alarm symptoms (weight loss, lack of appetite). 11. Prior use of other topical ointment for the treatment of haemorrhoid within 14 days before enrollment. 12. Pregnant and/or breastfeeding patients. 13. Participation in interventional research studies of investigational medicinal or device products (ongoing or terminated less than 30 days before screening).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the effect of Neofitoroid® in relieving discomfort symptoms after 10 days of treatment compared to baseline (pretreatment). | day 10 vs day 0 | Reduction of discomfort symptoms measured through a 0-100 Visual Analog Scale related to hemorrhoidal discomfort (VAS, from no symptoms to overwhelming symptoms, 100-mm scale) after 10 days of treatment compared to baseline. The higher values represent a worse outcome. Primary endpoint will be evaluated only with the hemorrhoidal discomfort VAS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relief in burning at 3, 7 and 10 days of treatment compared to baseline (pretreatment). | day 3, day 7 and day 10 vs day 0 | Reduction of burning symptoms measured through a 0-100 Visual Analog Scale related to hemorrhoidal burning (VAS, from no symptoms to overwhelming symptoms, 100-mm scale). The higher values represent a worse outcome. This secondary endpoint will be evaluated only with the hemorrhoidal burning VAS |
| Reduction of bleeding at 3, 7 and 10 days of treatment compared to baseline (pretreatment). | day 3, day 7 and day 10 vs day 0 | To evaluate the Reduction of bleeding as measured by a 6 point scale (never, rarely, sometimes, often, very often, always) for bleeding. |
| Reduction of anal leakage at 3, 7 and 10 days of treatment compared to baseline (pretreatment). | day 3, day 7 and day 10 vs day 0 | To evaluate the Reduction of anal leakage measured by a 6 point scale (never, rarely, sometimes, often, very often, always) for bleeding |
| Evaluation of presence of prolapse and/or nodules after 10 days of treatment compared to baseline (if present) | day 10 vs day 0 | To evaluate the Presence of prolapse and/or nodules after 10 days of treatment |
| Subject quality of life (EQ-5D-5L improvement after 10 days of treatment compared to baseline (pretreatment). | day 10 vs day 0 | To evaluate the Quality of life improvement measured with Quality of Life Index (EQ-5D-5L, MOVEMENT CAPACITY, PERSONAL CARE, LIVING ACTIVITIES, PAIN OR DISCOMFORT, ANXIETY OR DEPRESSION). The higher values represent a worse outcome. |
| Relief in discomfort symptom at 3 and 7 days of treatment compared to baseline (pretreatment). | day 3 and day 7 vs day 0 | To evaluate the Reduction of discomfort symptom measured through a 0-100 Visual Analog Scale related to hemorrhoidal discomfort (VAS, from no symptoms to overwhelming symptoms, 100-mm scale). The higher values represent a worse outcome. This secondary endpoint will be evaluated only with the hemorrhoidal discomfort VAS |
| Relief in pain symptom at 3, 7 and 10 days of treatment compared to baseline (pretreatment). | day 3, day 7 and day 10 vs day 0 | To evaluate the Reduction of pain symptom measured through a 0-100 Visual Analog Scale related to hemorrhoidal pain symptom (VAS, from no symptoms to overwhelming symptoms, 100-mm scale). The higher values represent a worse outcome. This secondary endpoint will be evaluated only with the hemorrhoidal pain symptom VAS |
| Relief in itching at 3, 7 and 10 days of treatment compared to baseline (pretreatment). | day 3, day 7 and day 10 vs day 0 | Reduction of itching symptoms measured through a 0-100 Visual Analog Scale related to hemorrhoidal itching (VAS, from no symptoms to overwhelming symptoms,100-mm scale). The higher values represent a worse outcome. This secondary endpoint will be evaluated only with the hemorrhoidal itching VAS |
| Absolute reduction of discomfort pre and post defecation at 3, 7, and 10 days of treatment compared to baseline (pretreatment). | day 3, day 7 and day 10 vs day 0 | Absolute reduction of discomfort pre and post defecation measured through a 0-100 Visual Analog Scale related to hemorrhoidal discomfort (VAS, from no symptoms to overwhelming symptoms, 100-mm scale). The higher values represent a worse outcome. This secondary endpoint will be evaluated through a compiled VAS pre-defecation and a compiled VAS post-defecation. This secondary endpoint will be evaluated through mean of the differences (VAS score post-defecation - VAS score pre-defecation) at differents time of study compared to the mean measured at baseline. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assessment of number of relapses between end of treatment and day 31 | day 31 vs day 10 | To evaluate the Number of relapses assessed between end of treatment and day 31, through patient telephone interview. |
| Safety and tolerability: analysis of adverse events and serious adverse events | from day -7 to day 31 | To evaluate safety and tolerability of NeoFitoroid® through the analysis of adverse events and serious adverse events that will be recorded throughout the duration of the study. |
| Assessment on type of defecation at day 0, 3, 7 and 10. | day 3, day 7 and day 10 vs day 0 | To evaluate the Assessment on type of defecation (normal, constipated or diarrheal) |
| Assessment on number of defecation at day 0, 3, 7 and 10. | day 3, day 7 and day 10 vs day 0 | To evaluate the Assessment on number of defecation |
Countries
Italy
Outcome results
None listed